Capital expenditure · 2011–2025
Neurocrine Biosciences capital expenditure
$34.0M−11.0% · FY2025
Neurocrine Biosciences (NBIX) reported $34.0M in capital expenditure for fiscal 2025, −11.0% year on year.
| Fiscal year | Capital expenditure | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $34.0M | −11.0% | Open → |
| FY20242024-12-31 | $38.2M | +35.0% | Open → |
| FY20232023-12-31 | $28.3M | +71.5% | Open → |
| FY20222022-12-31 | $16.5M | −29.5% | Open → |
| FY20212021-12-31 | $23.4M | +114.7% | Open → |
| FY20202020-12-31 | $10.9M | −25.9% | Open → |
| FY20192019-12-31 | $14.7M | −40.7% | Open → |
| FY20182018-12-31 | $24.8M | +257.3% | Open → |
| FY20172017-12-31 | $6.9M | +68.9% | Open → |
| FY20162016-12-31 | $4.1M | +112.4% | Open → |
| FY20152015-12-31 | $1.9M | +20.0% | Open → |
| FY20142014-12-31 | $1.6M | +195.8% | Open → |
| FY20132013-12-31 | $545,000 | −43.9% | Open → |
| FY20122012-12-31 | $971,000 | +29.5% | Open → |
| FY20112011-12-31 | $750,000 | — | Open → |
Capital expenditure — Capital expenditure is the cash the company spent during the year on property, plant and equipment — factories, stores, servers, vehicles. It appears in the investing section of the cash-flow statement as an outflow and is shown here as a positive amount. Operating cash flow minus this figure is free cash flow.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +31.3%
Capital expenditure at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Neurocrine Biosciences capital expenditure |url=https://companiesranked.com/en/company/neurocrine-biosciences/capital-expenditure |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Neurocrine Biosciences capital expenditure. CompaniesRanked. https://companiesranked.com/en/company/neurocrine-biosciences/capital-expenditureBibTeX
@misc{companiesranked-en-company-neurocrine-biosciences-capital-expenditure-2026,
author = {{CompaniesRanked}},
title = {{Neurocrine Biosciences capital expenditure}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/neurocrine-biosciences/capital-expenditure}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000914475-26-000007 · February 11, 2026
{{cite web |title=Neurocrine Biosciences capital expenditure — 10-K (0000914475-26-000007) |url=https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.